Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: Systems are described for measuring, recording, transmitting, accessing, and using an array of physical and physiological measurements that quantify states of complex adaptive systems, such as biological systems, more particularly the state is reflected in a metric designated health capacity. These measurements may be used, for example, for the pre-symptomatic detection and interception of disease states in a biological system. In one aspect, the system comprises a wearable device configured to measure, substantially simultaneously, an array of water-associated metrics, preferably at multiple loci on the biological system and as a function of time.

Abstract: The vessels weight is wholly or partially supported by one or more fully or partially submerged hydrofoil(s). The amount of lift provided by said hydrofoil(s) is regulated as a function of that lift itself. External variables such as trim angle and vessel velocity affect total lift, and this system compensates for those variables to provide a regulated lift without the need to directly sense any of the external variables. A typical control system comprises one or more sensory inputs, a method to translate the input into a control output, and an actuator that turns the outputs into actual movements. The only sensory input for this system is the same lifting force that is being regulated. The mechanical arrangement translates that lifting force into movements that produce negative feedback by varying the angle of attack of the hydrofoil, which in turn regulates the lift produced.

Abstract: An information system environment is described that, among other things, facilitates integration of electronic commerce and physical store front retailer selling channels. In some realizations, the system includes a shopper accessible kiosk co-located with a physical store front retailer and an electronic commerce information service accessible from locations external to the physical store front retailer. Both access inventory information supplied from a suitable information service. The shopper accessible kiosk allows a user thereof to access inventory information particular to the physical store front retailer, while the electronic commerce information service allows a user thereof to order items from out of stock of the physical store front retailer.

Abstract: An information system environment is described that, among other things, facilitates integration of electronic commerce and physical store front retailer selling channels. In some realizations, the system includes a shopper accessible kiosk co-located with a physical store front retailer and an electronic commerce information service accessible from locations external to the physical store front retailer. Both access inventory information supplied from a suitable information service. The shopper accessible kiosk allows a user thereof to access inventory information particular to the physical store front retailer, while the electronic commerce information service allows a user thereof to order items from out of stock of the physical store front retailer.

Abstract: An information system environment is described that, among other things, facilitates integration of electronic commerce and physical store front retailer selling channels. In some realizations, the system includes a shopper accessible kiosk co-located with a physical store front retailer and an electronic commerce information service accessible from locations external to the physical store front retailer. Both access inventory information supplied from a suitable information service. The shopper accessible kiosk allows a user thereof to access inventory information particular to the physical store front retailer, while the electronic commerce information service allows a user thereof to order items from out of stock of the physical store front retailer.

Abstract: A computer system, which may comprise a processor, a memory and a database, may implement a loss surface determining software module that forecasts a portfolio's loss surface. Daily loss histories may be collected from actual data or may be generated using a factor model. A model may generate a sequence of iid high frequency loss innovations that can be temporally aggregated with a Fourier transform. For each portfolio, the loss surface may be forecasted and 95% and 99% value-at-risk and expected shortfall forecasts may be derived for various time horizons.

Abstract: A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.

Abstract: A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.

Abstract: Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

Abstract: The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods.

Abstract: An invention forcing an aggregate risk model to be consistent with standalone models is provided. A revising transformation parameterized over and an objective function minimized over, the orthogonal group are provided, least changing cross blocks of covariance matrices, preserving information in original cross block correlations, consistent with a prescribed revised sub-block.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: The present invention provides non-alpha-tocopherol enriched tocopherol compositions and non-alpha-tocopherol metabolite enriched compositions for use in the reduction of inflammatory markers associated with inflammation such as C-reactive protein.

Abstract: Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

Abstract: Non-alpha-tocopherol enriched tocopherol compositions and non-alpha metabolite enriched compositions are disclosed for use in the reduction of the inflammatory marker IL-6.

Abstract: Disclosed are methods for the treatment of diabetes by administering a composition comprising a pharmaceutically acceptable amount of a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes. The invention is also directed to methods of controlling blood glucose level in diabetic patients with a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes.

Abstract: The present invention provides method for the treatment of a symptom of neuronal damage associated with cerebral ischemia comprising administering gamma-, beta-, or delta-tocopherol enriched tocopherol compositions.